Human group IIA secreted phospholipase A2 (GIIA) is a key enzyme in inflammatory reactions, worsening the condition of several chronic inflammatory diseases. The natural inhibitors of GIIA potentially block the production of inflammatory mediators. In the present study, elemolic acid, a triterpenoid fromBoswellia serratainhibited the GIIA enzyme in a concentration-dependent manner with IC50value of 5.70 ± 0.02 µM. The mode of GIIA inhibition was studied by increasing the concentration of the substrate from 30 to 120 nM, and calcium from 2.5 to 15 mM, the level of inhibition was not changed. The inhibitor-enzyme interaction was examined by fluorimetry and Circular Dichroism (CD) studies; elemolic acid altered intrinsic fluorescence intensity and shifted far UV- CD spectra of GIIA enzyme, suggesting the direct interaction with GIIA. Elemolic acid neutralized the GIIA mediated indirect hemolytic activity from 94.5 to 9.8% and reduced GIIA induced mouse paw edema from 171.75 to 113.68%. Elemolic acid also reduced the hemorrhagic effect of GIIA along withVipera russeliineurotoxic non-enzymatic peptide -VNTx-II (VR-HC-I). Thus, the elemolic acid has been proven as a potent inhibitor of GIIA enzyme and modulated the GIIA induced inflammatory response by in situ and in vivo methods.
Human Group IIA secreted phospholipase A2 (sPLA2-IIA) enzyme plays a crucial role in several chronic inflammatory diseases such asasthma, atherosclerosis, gout, bronchitis, etc. Several studies showed that the antioxidants exert an anti-inflammatory function by inhibiting the sPLA2-IIA enzyme. Hence, the present study evaluated an antioxidant molecule, sinapic acid, for sPLA2-IIA inhibition as an anti-inflammatory function. Initially, the antioxidant efficacy of sinapic acid was evaluated, and it showed greater antioxidant potency. Further, sinapic acid inhibited 94.4 ± 4.83% of sPLA2-IIA activity with an IC50 value of 4.16 ± 0.13 µM. The mode of sPLA2-IIA inhibition was examined by increasing the substrate concentration from 30 to 120nM and the calcium concentration from 2.5 to 15 mM, which did not change the level of inhibition. Further, sinapic acid altered the intrinsic fluorescence and distorted the far UltraViolet Circular Dichroism (UV-CD) spectra of the sPLA2-IIA, indicating the direct enzyme-inhibitor interaction. Sinapic acid reduced the sPLA2-IIA mediated hemolytic activity from 94 ± 2.19% to 12.35 ± 2.57% and mouse paw edema from 171.75 ± 2.2% to 114.8 ± 1.98%, demonstrating the anti-inflammatory efficiency of sinapic acid by in situ and in vivo methods, respectively. Finally, sinapic acid reduced the hemorrhagic effect of Vipera russelli venom hemorrhagic complex-I (VR-HC-I) as an anti-hemorrhagic function. Thus, the above experimental results revealed the sinapic acid potency to be an antioxidant, anti-inflammatory and anti-hemorrhagic molecule, and therefore, it appears to be a promising therapeutic agent.
Melastoma malabathricum is a medicinal plant found throughout Southeast Asian countries. Traditionally M. malabathricum was used for treating diseases such as hemorrhoids, cuts and wounds, toothache, and stomachache. Scientific findings also revealed the wide pharmacological actions of various parts of M. malabathricum such as anti-nociceptive, anti-inflammatory, wound healing, anti-diarrheal, cytotoxic, and antioxidant activities. The present study evaluated the mechanism of action of the anti-inflammatory activity of M. malabathricum. Initially different solvent extracts of M. malabathricum were evaluated for total phenolics, total flavonoids, anti-oxidant activity, antiinflammatory activity (protein denaturation), anti-cancer activity (prostate cancer cell line), and for sPLA2 inhibition. Results showed that ethanolic extract of Melastoma. malabathricum leaves showed higher phenolic and flavonoid concentrations, i.e. 36.77mg GAE/g dry wt. and 245.5 mg QE/gm of dry weight, respectively. Ethanol extract also exhibited the highest free radical scavenging activity in the DPPH method and phosphomolybdenum assay of which the IC50 values were 77.424 µg/ml and 95.159 µg/ml respectively. The anti-inflammatory assay (protein denaturation assay) of leaf extract showed the IC50 value of 45.518 µg/ml. Further, the extract exhibited greater sPLA2 inhibition (143.9 µg/ml) in the ELISA method against standard inhibitor thioetheramide-PC (6.73 µg/ml). Finally, the MTT assay for anti-cancer activity showed the IC50 value of 630.57 µg/ml against the standard cisplatin on the prostate cancer (PC-3) cell line.